raloxifene hydrochloride has been researched along with Chronic Kidney Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, T; Hijikata, Y; Matsubara, Y; Watanabe, N | 1 |
| Chu, Y; Gayleard, J; Jirru, E; Liu, MC; Rebholz, CM; Robinson, KA; Wilson, LM; Zhang, A | 1 |
| Collister, D; Connelly, K; Tangri, N | 1 |
| Cheng, MH; Lee, FK; Lee, WL; Tarng, DC; Wang, PH; Yang, WC | 1 |
| Farbodara, T; Haghverdi, F; Mortaji, S; Saidi, N; Soltani, P | 1 |
| Allen, MR; Brown, DM; Chen, N; Creecy, A; Granke, M; Hammond, MA; Moe, SM; Newman, CL; Nyman, JS; Tian, N; Wallace, JM | 1 |
| Frassetto, LA; Gordon, PL | 1 |
| Arnsten, JH; Blackwell, T; Cummings, SR; Ensrud, KE; Ishani, A; Melamed, ML; Neugarten, J; Silbiger, SR | 1 |
5 review(s) available for raloxifene hydrochloride and Chronic Kidney Diseases
| Article | Year |
|---|---|
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Topics: Antibodies, Monoclonal; Bias; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Femur Neck; Fractures, Spontaneous; Hip; Humans; Indoles; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spinal Fractures; Teriparatide; Thiophenes; Watchful Waiting | 2021 |
Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Topics: Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Teriparatide | 2017 |
Fracture risk and treatment in chronic kidney disease.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Risk Factors | 2018 |
The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
Topics: Bone Density; Estrogens; Female; Humans; Kidney; Osteoporosis; Raloxifene Hydrochloride; Renal Dialysis; Renal Insufficiency, Chronic; Selective Estrogen Receptor Modulators | 2013 |
Management of osteoporosis in CKD Stages 3 to 5.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Animals; Bone Density; Bone Density Conservation Agents; Calcitonin; Comorbidity; Diphosphonates; Female; Glomerular Filtration Rate; Humans; Life Style; Magnetic Resonance Imaging; Muscle Strength; Nandrolone; Nandrolone Decanoate; Nitric Oxide; Osteoporosis; Parathyroid Hormone; Phosphates; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Selective Estrogen Receptor Modulators; Teriparatide; Tomography, X-Ray Computed; Vitamin D Deficiency | 2010 |
2 trial(s) available for raloxifene hydrochloride and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5.
Topics: Administration, Oral; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Female; Humans; Hyperparathyroidism, Secondary; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus; Raloxifene Hydrochloride; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis.
Topics: Aged; Creatinine; Double-Blind Method; Female; Fractures, Bone; Glomerular Filtration Rate; Humans; Kidney; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Selective Estrogen Receptor Modulators | 2011 |
1 other study(ies) available for raloxifene hydrochloride and Chronic Kidney Diseases
| Article | Year |
|---|---|
Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.
Topics: Animals; Blood Urea Nitrogen; Bone Density Conservation Agents; Bone Remodeling; Collagen; Disease Models, Animal; Femur; Male; Mechanical Phenomena; Parathyroid Hormone; Polycystic Kidney, Autosomal Dominant; Raloxifene Hydrochloride; Rats; Renal Insufficiency, Chronic; Spine | 2016 |